Hikari Tsushin Inc. Has $20.66 Million Stock Holdings in Zoetis Inc. $ZTS

Hikari Tsushin Inc. lifted its position in Zoetis Inc. (NYSE:ZTS) by 295.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 164,238 shares of the company’s stock after buying an additional 122,744 shares during the period. Zoetis makes up about 1.3% of Hikari Tsushin Inc.’s portfolio, making the stock its 10th largest position. Hikari Tsushin Inc.’s holdings in Zoetis were worth $20,664,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in ZTS. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the 4th quarter valued at $25,000. Lodestone Wealth Management LLC acquired a new position in Zoetis in the 4th quarter worth $30,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis in the 3rd quarter worth $31,000. Holos Integrated Wealth LLC acquired a new position in Zoetis in the 4th quarter worth $32,000. Finally, Elyxium Wealth LLC acquired a new position in Zoetis in the 4th quarter worth $32,000. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other news, Director Michael B. Mccallister bought 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the purchase, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Finally, Bank of America upped their target price on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $133.92.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein Gewirtz & Grossman, the Schall Law Firm, DJS Law Group, and others, urged investors to join or lead a class action against Zoetis, keeping litigation risk in focus and potentially weighing on sentiment. Article Title
• Negative Sentiment: The lawsuits allege Zoetis misled investors about weakening veterinarian adoption and prescription trends, which could raise concerns about the company’s underlying growth outlook and create overhang on the stock. Article Title
• Neutral Sentiment: Rosen Law Firm and others reminded shareholders that July 27, 2026 is the lead-plaintiff deadline, but these notices are procedural and do not change Zoetis’ fundamentals by themselves. Article Title
• Neutral Sentiment: Bank of America Securities reportedly maintained a “Hold” rating on Zoetis, which suggests Wall Street remains cautious but not overtly bearish. Article Title

Zoetis Trading Up 0.3%

Zoetis stock opened at $81.51 on Friday. The firm has a 50-day moving average of $97.70 and a 200-day moving average of $114.47. Zoetis Inc. has a one year low of $72.38 and a one year high of $168.83. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company has a market cap of $34.17 billion, a price-to-earnings ratio of 13.52, a P/E/G ratio of 1.27 and a beta of 0.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the company earned $1.48 earnings per share. The company’s quarterly revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.